Can target-based drug discovery be reconciled with phenotypic assays in the context of drug repurposing? One of the questions discussed at the SLAS Drug Repurposing SIG meeting at SLAS2013.
Can target-based drug discovery be reconciled with phenotypic assays in the context of drug repurposing? One of the questions discussed at the SLAS Drug Repurposing SIG meeting at SLAS2013.
Mike generously is sharing this slide set which he presented at the 250th meeting of the ACS 2015 so that others who think they can not afford to run drug discovery can consider this economical distributed, virtual model….and to see CDD Vault in action.
“The Evolution of Pharmaceutical Biotechnology – Science, Strategies, Products, and Regulations”
Shows the latest developments in pharmaceutical biotechnology and provides a broad overview of biotherapeutic & biosimilar regulations globally and in the EU
Part of the MaRS Best Practices Series - Pre-Clinical development workshop
http://www.marsdd.com/bestpractices/
Speaker: Mike Watson. Exec Director Drug Development Services, Ricerca BioSciences
A presentation outlining the various processes a chemical compound undergoes (thorough & rigorous screening procedures) before it is finally introduced into the drug market
Personalized medicine involves the prescription of specific therapeutics best suited for an individual based on their genetic or proteomic profile. This talk discusses current approaches in drug discovery/development, the role of genetics in drug metabolism, and lawful/ethical issues surrounding the deployment of new health technology.
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical TrialsMaRS Discovery District
Part of the MaRS BioEntrepreneurship series session: Clinical Trials Strategy
Speaker: Beatrice Setnik
This is available as an audio presentation:
http://www.marsdd.com/bioent/feb12
Also view the event blog and summary:
http://blog.marsdd.com/2007/02/14/bioentrepreneurship-clinical-trial-strategies-its-never-too-soon/
Personalized medicine involves the prescription of specific therapeutics best suited for an individual based on their genetic or proteomic profile. This talk discusses current approaches in drug discovery/development, the role of genetics in drug metabolism, and lawful/ethical issues surrounding the deployment of new health technology. I highlight some bioinformatic roles in the drug discovery process, and discuss the use of semantic web technologies for data integration and knowledge discovery..
Mike generously is sharing this slide set which he presented at the 250th meeting of the ACS 2015 so that others who think they can not afford to run drug discovery can consider this economical distributed, virtual model….and to see CDD Vault in action.
“The Evolution of Pharmaceutical Biotechnology – Science, Strategies, Products, and Regulations”
Shows the latest developments in pharmaceutical biotechnology and provides a broad overview of biotherapeutic & biosimilar regulations globally and in the EU
Part of the MaRS Best Practices Series - Pre-Clinical development workshop
http://www.marsdd.com/bestpractices/
Speaker: Mike Watson. Exec Director Drug Development Services, Ricerca BioSciences
A presentation outlining the various processes a chemical compound undergoes (thorough & rigorous screening procedures) before it is finally introduced into the drug market
Personalized medicine involves the prescription of specific therapeutics best suited for an individual based on their genetic or proteomic profile. This talk discusses current approaches in drug discovery/development, the role of genetics in drug metabolism, and lawful/ethical issues surrounding the deployment of new health technology.
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical TrialsMaRS Discovery District
Part of the MaRS BioEntrepreneurship series session: Clinical Trials Strategy
Speaker: Beatrice Setnik
This is available as an audio presentation:
http://www.marsdd.com/bioent/feb12
Also view the event blog and summary:
http://blog.marsdd.com/2007/02/14/bioentrepreneurship-clinical-trial-strategies-its-never-too-soon/
Personalized medicine involves the prescription of specific therapeutics best suited for an individual based on their genetic or proteomic profile. This talk discusses current approaches in drug discovery/development, the role of genetics in drug metabolism, and lawful/ethical issues surrounding the deployment of new health technology. I highlight some bioinformatic roles in the drug discovery process, and discuss the use of semantic web technologies for data integration and knowledge discovery..
BioVariance - Pediatric Pharmacogenomics in Drug DiscoveryJosef Scheiber
This slideset gives an overview of pharmacogenomic and pediatric dosing knowledge and various influence factors. Finally it shows an example on how to use this kind of Data within predictive approaches.
Mobile Health Forum Frankfurt - Therapieempfehlung per SmartphoneJosef Scheiber
Vortrag zeigt Überblick zum Thema plus die Entwicklung unserer Datenbank/App im Bereich "Personalisierte Medizin im Kindesalter" sowie die dafür nötige Datenerfassung
A comparison predictive and adaptive approach - Main differences - When to apply an agile approach? - When a predictive one? - A comparison between PMP® and PMI-ACP® - How to choose between them?
Pattern - an open source project for migrating predictive models from SAS, et...DataWorks Summit
"Pattern" is an open source project which takes models trained in popular analytics frameworks, such as SAS, Microstrategy, SQL Server, etc., and runs them at scale on Apache Hadoop. This machine learning library works by translating PMML -- an established XML standard for predictive model markup -- into data workflows based on the Cascading API in Java. PMML models can be run in a pre-defined JAR file with no coding required. PMML can also be combined with other flows based on ANSI SQL (Lingual), Scala (Scalding), Clojure (Cascalog), etc. Multiple companies have collaborated to implement parallelized algorithms: Random Forest, Logistic Regression, K-Means, Hierarchical Clustering, etc., with more machine learning support being added. Benefits include greatly reduced development costs and less licensing issues at scale ?- while leveraging a combination of Apache Hadoop clusters, existing intellectual property in predictive models, and the core competencies of analytics staff. Sample code in the talk will show apps using predictive models built in SAS and R, e.g., anti-fraud classifiers. In addition, examples will show how to compare variations of models for large-scale customer experiments. Portions of this material come from the O`Reilly book "Enterprise Data Workflows with Cascading", due June 2013.
Twitter: @NycDataSci
Learn with our NYC Data Science Program (weekend courses for working professionals and 12 week full time for whom are advancing their career into Data Science)
Our next 12-Week Data Science Bootcamp starts in Jun. (Deadline to apply is May 1st, all decisions will be made by May 15th.)
====================================
Max Kuhn, Director is Nonclinical Statistics of Pfizer and also the author of Applied Predictive Modeling.
He will join us and share his experience with Data Mining with R.
Max is a nonclinical statistician who has been applying predictive models in the diagnostic and pharmaceutical industries for over 15 years. He is the author and maintainer for a number of predictive modeling packages, including: caret, C50, Cubist and AppliedPredictiveModeling. He blogs about the practice of modeling on his website at ttp://appliedpredictivemodeling.com/blog
---------------------------------------------------------
His Feb 18th course can be RSVP at NYC Data Science Academy.
Syllabus
Predictive Modeling using R
Description
This class will get attendees up to speed in predictive modeling using the R programming language. The goal of the course is to understand the general predictive modeling process and how it can be implemented in R. A selection of important models (e.g. tree-based models, support vector machines) will be described in an intuitive manner to illustrate the process of training and evaluating models.
Prerequisites:
Attendees should have a working knowledge of basic R data structures (e.g. data frames, factors etc) and language fundamentals such as functions and subsetting data. Understanding of the content contained in Appendix B sections B1 though B8 of Applied Predictive Modeling (free PDF from publisher [1]) should suffice.
Outline:
- An introduction to predictive modeling
- R and predictive modeling: the good and bad
- Illustrative example
- Measuring performance
- Data splitting and resampling
- Data pre-processing
- Classification trees
- Boosted trees
- Support vector machines
If time allows, the following topics will also be covered
- Parallel processing
- Comparing models
- Feature selection
- Common pitfalls
Materials:
Attendees will be provided with a copy of Applied Predictive Modeling[2] as well as course notes, code and raw data. Participants will be able to reproduce the examples described in the workshop.
Attendees should have a computer with a relatively recent version of R installed.
About the Instructor:
More about Max's work:
[1] http://rd.springer.com/content/pdf/bbm%3A978-1-4614-6849-3%2F1.pdf
[2] http://appliedpredictivemodeling.com
International competition, shorter product life cycles and faster technological leaps forward – these are only a few of the challenges the production of a company is facing in the 21st century. In order to survive in an environment like this, resource-efficient and secure planning of production processes are necessary to guarantee a consistent and high quality output. Unforeseeable machine failures as well as performance drops or deterioration in quality because of defective system components can lead to shortness of supplies which will eventually weaken the market position of the entire organization.
To meet these requirements organizations are increasingly focusing on the improvement of maintenance, repair and operations of their machinery. In the previous years, the industry shifted their focus away from only reactive repair mechanisms towards the predictive coordination of machine maintenance.
Predictive Maintenance falls under the category of the future of maintenance developments. Originally developed in the course of the “Industrie 4.0” high-tech strategy of the German government, today Predictive Maintenance represents the informatization of production processes - intelligent IT-based production systems on the path towards a Smart Factory. Through the generation and analysis of different machine data, the predictive power of the state of industrial plants is not only enhanced, but also provides the basis for an improved planning certainty as well as the efficient planning of repair and maintenance work.
[Tutorial] building machine learning models for predictive maintenance applic...PAPIs.io
This talk introduces the landscape and challenges of predictive maintenance applications in the industry, illustrates how to formulate (data labeling and feature engineering) the problem with three machine learning models (regression, binary classification, multi-class classification) using a publicly available aircraft engine run-to-failure data set, and showcases how the models can be conveniently trained and compared with different algorithms in Azure ML.
Chemotherapy is a type of treatment to cancer patients in a way to reduce the risk of cancer and stops the severity of level
for more Visit surgicaltechie.com
A malignant progressive disease in which the bone marrow and other blood-forming organs produce increased numbers of immature or abnormal leucocytes. These suppress the production of normal blood cells, leading to anemia and other symptoms.
The incidence of childhood ALL is approximately 3- 4 cases per 100,000 children under the age of 15 years
Slideshow is from the University of Michigan Medical School’s M2 Musculoskeletal sequence
View additional course materials on Open.Michigan:
openmi.ch/med-M2Muscu
Epilepsy Management: Key issues and challengesPramod Krishnan
This brief presentation summarises the key issues and challenges in Epilepsy management, including diagnosis, treatment, compliance, special populations, adverse effects, psychiatric comorbidities and ASM withdrawal.
Overview of Scleroderma, Raynaud's Phenomenon and Current Treatments - Presented by Dr. Nadera Swiss at the Scleroderma Foundation Greater Chicago Chapter's Patient Education Conference on Saturday, April 27, 2019
Similar to Bio variance j_scheiber_bioit_repurposingworkshop2013_draft (20)
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024Neo4j
Neha Bajwa, Vice President of Product Marketing, Neo4j
Join us as we explore breakthrough innovations enabled by interconnected data and AI. Discover firsthand how organizations use relationships in data to uncover contextual insights and solve our most pressing challenges – from optimizing supply chains, detecting fraud, and improving customer experiences to accelerating drug discoveries.
In the rapidly evolving landscape of technologies, XML continues to play a vital role in structuring, storing, and transporting data across diverse systems. The recent advancements in artificial intelligence (AI) present new methodologies for enhancing XML development workflows, introducing efficiency, automation, and intelligent capabilities. This presentation will outline the scope and perspective of utilizing AI in XML development. The potential benefits and the possible pitfalls will be highlighted, providing a balanced view of the subject.
We will explore the capabilities of AI in understanding XML markup languages and autonomously creating structured XML content. Additionally, we will examine the capacity of AI to enrich plain text with appropriate XML markup. Practical examples and methodological guidelines will be provided to elucidate how AI can be effectively prompted to interpret and generate accurate XML markup.
Further emphasis will be placed on the role of AI in developing XSLT, or schemas such as XSD and Schematron. We will address the techniques and strategies adopted to create prompts for generating code, explaining code, or refactoring the code, and the results achieved.
The discussion will extend to how AI can be used to transform XML content. In particular, the focus will be on the use of AI XPath extension functions in XSLT, Schematron, Schematron Quick Fixes, or for XML content refactoring.
The presentation aims to deliver a comprehensive overview of AI usage in XML development, providing attendees with the necessary knowledge to make informed decisions. Whether you’re at the early stages of adopting AI or considering integrating it in advanced XML development, this presentation will cover all levels of expertise.
By highlighting the potential advantages and challenges of integrating AI with XML development tools and languages, the presentation seeks to inspire thoughtful conversation around the future of XML development. We’ll not only delve into the technical aspects of AI-powered XML development but also discuss practical implications and possible future directions.
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...Neo4j
Leonard Jayamohan, Partner & Generative AI Lead, Deloitte
This keynote will reveal how Deloitte leverages Neo4j’s graph power for groundbreaking digital twin solutions, achieving a staggering 100x performance boost. Discover the essential role knowledge graphs play in successful generative AI implementations. Plus, get an exclusive look at an innovative Neo4j + Generative AI solution Deloitte is developing in-house.
Unlocking Productivity: Leveraging the Potential of Copilot in Microsoft 365, a presentation by Christoforos Vlachos, Senior Solutions Manager – Modern Workplace, Uni Systems
Climate Impact of Software Testing at Nordic Testing DaysKari Kakkonen
My slides at Nordic Testing Days 6.6.2024
Climate impact / sustainability of software testing discussed on the talk. ICT and testing must carry their part of global responsibility to help with the climat warming. We can minimize the carbon footprint but we can also have a carbon handprint, a positive impact on the climate. Quality characteristics can be added with sustainability, and then measured continuously. Test environments can be used less, and in smaller scale and on demand. Test techniques can be used in optimizing or minimizing number of tests. Test automation can be used to speed up testing.
Dr. Sean Tan, Head of Data Science, Changi Airport Group
Discover how Changi Airport Group (CAG) leverages graph technologies and generative AI to revolutionize their search capabilities. This session delves into the unique search needs of CAG’s diverse passengers and customers, showcasing how graph data structures enhance the accuracy and relevance of AI-generated search results, mitigating the risk of “hallucinations” and improving the overall customer journey.
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...SOFTTECHHUB
The choice of an operating system plays a pivotal role in shaping our computing experience. For decades, Microsoft's Windows has dominated the market, offering a familiar and widely adopted platform for personal and professional use. However, as technological advancements continue to push the boundaries of innovation, alternative operating systems have emerged, challenging the status quo and offering users a fresh perspective on computing.
One such alternative that has garnered significant attention and acclaim is Nitrux Linux 3.5.0, a sleek, powerful, and user-friendly Linux distribution that promises to redefine the way we interact with our devices. With its focus on performance, security, and customization, Nitrux Linux presents a compelling case for those seeking to break free from the constraints of proprietary software and embrace the freedom and flexibility of open-source computing.
DevOps and Testing slides at DASA ConnectKari Kakkonen
My and Rik Marselis slides at 30.5.2024 DASA Connect conference. We discuss about what is testing, then what is agile testing and finally what is Testing in DevOps. Finally we had lovely workshop with the participants trying to find out different ways to think about quality and testing in different parts of the DevOps infinity loop.
UiPath Test Automation using UiPath Test Suite series, part 6DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 6. In this session, we will cover Test Automation with generative AI and Open AI.
UiPath Test Automation with generative AI and Open AI webinar offers an in-depth exploration of leveraging cutting-edge technologies for test automation within the UiPath platform. Attendees will delve into the integration of generative AI, a test automation solution, with Open AI advanced natural language processing capabilities.
Throughout the session, participants will discover how this synergy empowers testers to automate repetitive tasks, enhance testing accuracy, and expedite the software testing life cycle. Topics covered include the seamless integration process, practical use cases, and the benefits of harnessing AI-driven automation for UiPath testing initiatives. By attending this webinar, testers, and automation professionals can gain valuable insights into harnessing the power of AI to optimize their test automation workflows within the UiPath ecosystem, ultimately driving efficiency and quality in software development processes.
What will you get from this session?
1. Insights into integrating generative AI.
2. Understanding how this integration enhances test automation within the UiPath platform
3. Practical demonstrations
4. Exploration of real-world use cases illustrating the benefits of AI-driven test automation for UiPath
Topics covered:
What is generative AI
Test Automation with generative AI and Open AI.
UiPath integration with generative AI
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
UiPath Test Automation using UiPath Test Suite series, part 5DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 5. In this session, we will cover CI/CD with devops.
Topics covered:
CI/CD with in UiPath
End-to-end overview of CI/CD pipeline with Azure devops
Speaker:
Lyndsey Byblow, Test Suite Sales Engineer @ UiPath, Inc.
In his public lecture, Christian Timmerer provides insights into the fascinating history of video streaming, starting from its humble beginnings before YouTube to the groundbreaking technologies that now dominate platforms like Netflix and ORF ON. Timmerer also presents provocative contributions of his own that have significantly influenced the industry. He concludes by looking at future challenges and invites the audience to join in a discussion.
A tale of scale & speed: How the US Navy is enabling software delivery from l...sonjaschweigert1
Rapid and secure feature delivery is a goal across every application team and every branch of the DoD. The Navy’s DevSecOps platform, Party Barge, has achieved:
- Reduction in onboarding time from 5 weeks to 1 day
- Improved developer experience and productivity through actionable findings and reduction of false positives
- Maintenance of superior security standards and inherent policy enforcement with Authorization to Operate (ATO)
Development teams can ship efficiently and ensure applications are cyber ready for Navy Authorizing Officials (AOs). In this webinar, Sigma Defense and Anchore will give attendees a look behind the scenes and demo secure pipeline automation and security artifacts that speed up application ATO and time to production.
We will cover:
- How to remove silos in DevSecOps
- How to build efficient development pipeline roles and component templates
- How to deliver security artifacts that matter for ATO’s (SBOMs, vulnerability reports, and policy evidence)
- How to streamline operations with automated policy checks on container images
Pushing the limits of ePRTC: 100ns holdover for 100 daysAdtran
At WSTS 2024, Alon Stern explored the topic of parametric holdover and explained how recent research findings can be implemented in real-world PNT networks to achieve 100 nanoseconds of accuracy for up to 100 days.
Pushing the limits of ePRTC: 100ns holdover for 100 days
Bio variance j_scheiber_bioit_repurposingworkshop2013_draft
1. Drug Repurposing –
Fishing for Pearls with a very wide net
Josef Scheiber, PhD
BioIT Workshop
April 9, 2013
2. Significant unmet medical need
100%
90%
80%
NSAIDS 80 % response rate
Drug response rate
70%
60%
50%
40%
30% Alzheimer 25 % response rate
20%
10% Several thousand diseases without
0%
known treatment
diseases
3. Disease understanding is getting better and better
Example: Leukemia and Lymphoma
5 Year 1950 Disease of
the Blood
Survival
~0% 1960 Leukemia Lymphoma
Increasing understanding of underlying biology
1970 Chronic
Leukemia
Acute
Leukemia
Preleukemia
Indolent
Lymphoma
Aggressive
Lymphoma
opens up new hypotheses
2010
~ 70%
4. Overview – Drug Repurposing
• Background
• The Sirota/Butte approach: Rebuilding the paper
– Workflow & Results
• Extensions: Orthogonal evidence from biological
networks & rare disease information
5. Drug repurposing
• Has becomes a matter of intense interest during the
past few years
≡ • The concept originally evolved in the early 1990s
• Drug repositioning • Is a strategic approach to drug development to extract
added value from prior research and development
• Drug reprofiling investments
• Drug retasking • Reinvestigation of drug candidates that have not
succeeded in advanced clinical trials, for reasons other
than safety, for potential new therapeutic applications
6. What we ultimately want to have
Molecular inititating event(s) What signalling pathways are affected?
How does this translate into gene expression changes?
How does this impact the phenotype? What drug targets are good to interfere with
The phenotype? Does a known drug interact with one of these targets?
8. Drug target network as reminder
Key message:
Every drug binds a significant number of targets
Yildirim MA, Goh KI, Cusick ME, Barabási AL, Vidal M. Drug-target network.
Nat Biotechnol. 2007 Oct;25(10):1119-26.
9. Dealing with a very complex environment –
i.e. many opportunities
DNA Target
RNA Off-targets
Protein Metabolites
Interactions Additional indications
Clinical parameters Unspecific effects
Treatment History Similar drugs
Tissue anatomy
Surgical History
Epigenetic Profiles from many
patients at different
timeponits
Adapted from: J. Scheiber; How can we enable drug discovery informatics for personalized healthcare?
Expert Opinion on Drug Discovery, 1-6; 2/2011
10. There are quite a few successful examples
Drug Original indication New indication
Sildenafil Angina Male erectile dysfunction
Eflomithine Anti-infective Reduction of unwanted facial hair in women
Finasteride Benign prostatic hyperplasia Hair loss
Raloxifene Breast and prostate cancer Osteoporosis
Paclitaxel Cancer Restenosis
Zidovudine Cancer HIV/AIDS
Topiramate Epilepsy Obesity
Minoxidil Hypertension Hair loss
Phentolamine Hypertension Impaired night vision
Tadalafil Inflammation and cardiovascular disease Male erectile dysfunction
Mecamylamine Moderately severe to severe essential hypertension ADHD
and uncomplicated cases of malignant hypertension
Celecoxib Osteoarthritis and adult Familial adenomatous polyposis, colon and breast cancer
Mifepristone Pregnancy termination Psychotic major depression
Thalidomide Sedation, nausea and insomnia Cutaneous manifestations of moderate to severe erythema
nodosum leprosy and multiple myelome
Dapoxetine Analgesia Depression Premature ejaculation
Chlorpromazine Anti-emetic / antihistamine Non-sedating tranquillizer
Tofisopam Anxiety-related conditions Irritable bowel syndrome
Fluoxetine Depression Premenstrual dysphoria
Sibutramine Depression Obesity
Bupropion Depression Smoking cessation
Duloxetine Depression Stress urinary incontinence
Milnacipran Depression Fibromyalgia syndrome
Ropinirole Hypertension Parkinson’s disease and idiopathic restless leg syndrome
Lidocaine Local anaesthesia Oral corticosteroid-dependent asthma
Atomoxetine Parkinson’s disease ADHD
Galantamine Polio, paralysis Alzheimer’s disease
11. The two major “schools” of
repurposing
Disease Profiles Compound Binding Profiles, compound
Differences in Activity Profiles, can be mediated indications linked to immediate targets
through pathways
Diseases with similar gene expression profiles Compound binding profiles are similar
are treated in a similar way Drug-target network
Match drug profiles (chembank, connectivity Explain drug profiles
map)
Extend to similar Diseases (Barabasi
Diseasasome)
OMIM, GWAS ,,
,,
Focus for today
12. Core Idea: Every biological state can be
described by a given gene expression signature
2259 Genes
Gsc
siE-Cadherin
TGFβ
Twist
Snail
Gene Expression Value
-3.0 3.0
Harrison, C. Translational genetics: Signatures for drug repositioning. Nat Rev Genet, 2011
Lukk, M et al. A global map of human gene expression. Nat Biotech, 2010
Dudley, J.T. et al. Disease signatures are robust across tissues and experiments. Mol Sys Biol, 2009
Culhane, A.C. et al. GeneSigDB--a curated database of gene expression signatures
Nucleic Acids Res, 2009
Nevins, J.R. & Potti, A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet, 2007
Lamb, J.et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease
Science, 2006
Source: adapted from Taube et al, PNAS 2010
13. Starting data: Connectivity map
Every drug response can be described by a given
gene expression signature
Genome-wide differential expression
profiles as ranked lists of genes
UP-regulated genes
Null effect
Down-regulated genes
Small molecules: Cell lines: Concentration and treatment
• 1309 perturbagens tested • MCF7 (human epitelial breast cancer) • 10mM (when the optimal concentration is
(FDA approved and nondrug bioactive • PC3 (human epitelial prostate cancer) unknown) x 6h
compounds) • HL60 (human leukemia)
Negative control
• SKMEL5 (human melanoma)
• ssMCF7 (MCF7 grown in a different vehicle) • Cell in the same plate and treated with
vehicle alone (medium, DMSO…)
Lamb, J. The connectivity map: a new tool for biomedical research. Nat Rev Cancer 7, 54-60 (2007)
Lamb, J. et al. The connectivity map: using gene-expression signatures to connect
small molecules, genes, and disease. Science 313, 1929-1935 (2006)
14. Drugs ”reverting” a phenotype signature
”revert the phenotype”
A B
Reference database of drug gene expression
Genes
Disease individuals Treated samples
Drugs
Healthy controls Untreated samples
Disease gene expression Drug gene
signature expression profile
Discovery and preclinical validation of drug indications using
compendia of public gene expression data
Source: Sirota et al. Sci Trans Med 2011
15. Genome-based drug re-purposing approaches
1 2
Drugs able to “revert” a phenotype signature Drugs eliciting similar transcriptional
could “revert the phenotype”, i.e. influence responses could share therapeutic effects
the disease and its progression
Disease Drug response
signature signature
Therapeutic effect
No mechanistic insights
16. Disease neighbors & drug neighbors
• Neighboring diseases may share the same drugs
• Computational drug repurposing
Chiang AP, Butte AJ
Clinical Pharma and Therapeutics. 2009
Dudley J, Tibshirani R, Butte AJ
Molecular Systems Biology, 2009
Source: Sirota et al. Sci Trans Med 2011
17. Predicting new indications –
Cimetidine as an example
“To perform an initial experimental evaluation
of our approach, we chose to evaluate
one of the therapeutic predictions
for lung adenocarcinoma (LA), because
lung cancer contributes the greatest burden
of cancer mortality and incidence
in Europe and the United States.
Although our methodology predicted
multiple new therapeutic relationships
for LA, we chose to test cimetidine because
it is an off-patent and inexpensive
drug available over the counter in the
United States and has a favorable side effect
profile . Our prediction score of
−0.088 for cimetidine was moderate, but
still more significant than the score of
−0.075 for gefitinib, a well-known therapy
for LA.”
Source: Sirota et al. Sci Trans Med 2011
18. One more example:
Topiramate (antiepileptic) for Crohn’s disease
Drug-disease score A
-0,30 -0,20 -0,10 0,00
5186324
Topiramate
Prednisolone
12,13-EODE
Tolbutamide
Yohimbine
5213008
Tomelukast
Phenanthridinone
5162773 B. Gross pathology score
5151277
Clotrimazole 5
5140203 4
Genistein
Fasudil 3 ****
5230742 2
5182598
1
Computational Repositioning of the Anticonvulsant Topiramate for 0
Inflammatory Bowel Disease TNBS + veh TNBS + pred TNBS + top Vehicle
* Prednisolone = Established compound for Crohn’s disease
** Trinitobenzene Sulfonic Acid (TNBS)
Source: Dudley et al, Sci Trans Med 2011
19. General impression - Caveats
• Need for gene expression profile measurements on the candidate drugs, data are publicly
available for > 1000, numerous relevant compounds not yet tested
• not clear how drug performance in a breast cancer cell line is relevant to all types of
diseases effects of drugs on gene expression across disease tissues
• Disease-related microarray data can and should be combined with other types of
knowledge on drugs
• Therapeutic efficacy is more complex than a simple matching of expression profiles.
Compounds have to reach the appropriate tissue to have an effect. Tissueagnostic
Methodology (the disease and drug gene expression was not measured on the same
tissues) might be suitable to find both direct and distant effects of drugs.
• Although findings for cimetidine will need further preclinical testing and demonstration in
larger clinical trials, the concept of computational analysis of public gene expression
databases as a potentially useful approach to drug discovery that may uncover additional
uses for approved drugs is given
20. Rebuilding the Sirota/Butte analysis
• chose 3 datasets in GEO concerning lung tumors in order to compare results to those obtained in
the paper : GSE2514 as analysed in the paper, GSE10072 and GSE7670 (both using Affymetrix
U133A chips) for further validation
• used gcRMA algorithm to normalize each of them and as recommended by Sirota et al., applied a
rank normalization on expression data.
• Concerning the GSE2514: converted the U95av2 probeset-ID into U133A probeset-ID (as the drug-
signatures, availables in Connectivity Map are based on U133A chips, not specifically mentioned in
the paper). In cases where several U95av2 probes map to the same U133A probe, averaged the
signal and calculated the normalized rank.
• Compared control samples to disease samples using SAM algorithm (“wilc.stat” option used to
perform Wilcoxon test on ranked data) with a FDR threshold of 0.05 for q-values
• obtained large lists of up- and down regulated genes (thousands of genes) in each datasets. As the
tool available on the Connectivity Map website only accept lists up to 300 genes, selected each the
150 most significative up- and down-regulated genes in each dataset to create disease signatures
in the analysis
Special thanks: J.P Meyniel, ISoft
.
21. The tool used: AMADEA from ISoft
Courtesy: J.P Meyniel, St. Graziani; ISoft
.
22. Rebuilding the Sirota/Butte analysis
• Download the signatures from Connectivity Map website, obtain results for each dataset
The results are relevant and consistent between the datasets:
• PHA-00665752 is found at the top of the 3 lists when you order enrichment from -1 to 1.
This molecule was shown to suppress KRAS-induced lung preneoplasia by inhibition of the Met receptor tyrosine kinase
(http://www.aacrmeetingabstracts.org/cgi/content/abstract/2006/1/416 ) ==> “Short-term treatment with a small
molecule inhibitor of c-met (PHA-00665752) decreased the size of atypical alveolar hyperplasia (AAH) and adenomas and,
within these lesions, reduced the phosphorylation of AKT, a pro-survival mediator of c-met, and induced apoptosis of
vascular endothelial cells and alveolar epithelial cells”
• Top hits all with known modes of action in Oncology
HDAC inhibitor MS-275 is found in the top 5 molecules in GSE7670 and GSE10072 datasets and in
position 174 in GSE2514 (enrichment -0.499).
This molecule is used in several clinical trials: Hodgkin’s lymphomas, breast cancer (in combination with aromatase
inhibitors) and metastatic lung cancer (in combination with erlotinib). This drug promotes differenciation and apoptosis
(http://cancerres.aacrjournals.org/content/63/13/3637 )
• Another HDAC inhibitor, HC-toxin, is found in the top 5 molecules in GSE2514.
• Celastrol, a natural proteasome inhibitor is found in the top 5 molecules in each dataset .
This drug is a potent antioxidant and anti-inflammatory molecule was shown to suppress androgen-independent prostate
cancer progression (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0014153 )
23. Surprise
However, contrary to the paper of Sirota
et al., didn’t find Cimetidine as significant
hit:
GSE2514: enrichment 0.249
GSE10072: enrichment 0.249
GSE7670: enrichment -0.237
24. Possible reasons for the difference
with Cimetidine
• Time difference when analyses where run
• Selection by Sirota not driven by computational
results only (explicitly mentioned in the paper)
25. Going a step further
1 2
?
Drugs eliciting similar transcriptional
Drugs able to “revert” a phenotype signature
responses could share therapeutic effects
could “revert the phenotype”
Disease Drug response
signature signature
How can we get to mechanistic insights?
Therapeutic effect
26. Going a step further
• Trying to find a molecular initiating event that leads
to gene expression changes
• A computational dive into the biology underlying the
hypotheses
• Workflow:
Take most relevant genes from profiles map
into pathways retrieve most-affected
pathways retrieve small molecules active in
those pathways / annotate targets in the
pathways with additional valuable data sources
to link diseases
27. On-Pathway Repurposing
Primary or secondary target of Drug X
Gene expression level affected
Genetic link to rare disease
Treating a disease/symptom
29. Data sources
Rare disease fishing
for initial indication
Retrieve and sort
Take affected Match into (Further mapping),
pathways by
genes from pathways from e.g. rare diseases
number of
previous analysis Reactome or GWAS
affected targets
What biology most affected?
Several immune-system relevant pathways
Gene expression-affecting pathways
Developmental biology
Insuline metabolism
PI3K/AKT signalling
30. Annotate targets with diseases
Individually Rare – Collectively common (10%)
Diseases for which testing is available
2443 diseases (~6000 genes) are highly predictive & medically actionable
2.000
1.800
1.600
1.400
1.200
3 rare diseases linked to Lung cancer example
1.000 (example: a rare genetically determined asthma)
800
600
400
200
0
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Source: Genetests.org
31. More annotation:
Genome-Wide Association Studies (GWAS)
As of 2011,
1200 human
GWASs have
been
published on
over 400 traits
Manolio TA. N Engl J
Med 2010;363:166-176.
32. One more step: Small molecules
from chemogenomic DBs,
• Example: ChEMBL
• What indications are they approved for
• Can these compounds used in the indication
being scrutinized
33. Outlook
• The right drug for the right patient at the right time & right dose is
only possible if you have the right knowledge within the right context
right in place
• Number of known off-targets increases repurposing opportunities
gamble with safety
• massive quantity of public available gene expression data has not yet
been fully exploited (e.g. disease profile fishing with drug expression
profile, we are attempting this now)
• Identified rare diseases can be used as point of entry for clinical
trials